Umeå universitets logga

umu.sePublikationer
Ändra sökning
RefereraExporteraLänk till posten
Permanent länk

Direktlänk
Referera
Referensformat
  • apa
  • ieee
  • vancouver
  • Annat format
Fler format
Språk
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Annat språk
Fler språk
Utmatningsformat
  • html
  • text
  • asciidoc
  • rtf
Effectiveness of first generation disease-modifying therapy to prevent conversion to secondary progressive multiple sclerosis
Department of Clinical Neuroscience, Institute of Neuroscience and Physiology, the Sahlgrenska Academy, University of Gothenburg. Department of Neurology, Sahlgrenska University Hospital, Göteborg, Sweden.
Neuroimmunology Unit., Department of Clinical Neuroscience, Karolinska Institute, CMM L8:4 Karolinska University Hospital Solna, Stockholm, Sweden.
Department of Clinical Neuroscience, Institute of Neuroscience and Physiology, the Sahlgrenska Academy, University of Gothenburg. Department of Neurology, Sahlgrenska University Hospital, Göteborg, Sweden.
Department of Clinical Neuroscience, Karolinska Institute, Stockholm, Sweden.
Visa övriga samt affilieringar
2022 (Engelska)Ingår i: Multiple Sclerosis and Related Disorders, ISSN 2211-0348, E-ISSN 2211-0356, Vol. 68, artikel-id 104220Artikel i tidskrift (Refereegranskat) Published
Abstract [en]

Background: The use of disease-modifying therapies (DMTs) in multiple sclerosis (MS) has been associated with reduced relapse rates and accumulation of disability. However, studies examining impact of DMT on risk of transition to secondary progressive MS (SPMS) leveraging population-based nationwide data are still rare. Here, we determine the population incidence of conversion to SPMS using two consecutive nation-wide cohorts, one immediately before and one after the introduction of DMT in Sweden.

Methods: We included two consecutive population cohorts of relapsing-remitting MS (RRMS) from the Swedish national MS register for the periods 1975–1994 (n = 2161), before DMT availability, and 1995–2011 (n = 3510), in which DMTs, mainly first generation DMT (injectables), became available and eventually were used by 70% of patients. We explored the risk of transition to SPMS as a calendar year function encompassing the two cohorts. In addition, we determined the incidence of transition to SPMS through age strata below and above 50 years in untreated and treated patient subgroups.

Results: The risk of conversion to SPMS (adjusted for current age, current time since onset, calendar year and sex) was significantly lower in the second compared with the first population cohort (hazard ratio 0.58; CI 0.48, 0.70). The risk of SPMS conversion per calendar year decreased by 2.6% annually (p < 0.001) after 1995. The risk of SPMS conversion increased with age until age 50. Thereafter, it was unchanged or decreased among those with early MS onset age (<35 years), but continued to increase with onset at higher age, with similar trends in treated and untreated subgroups.

Conclusion: The incidence of SPMS conversion significantly decreased at the population level after introduction of first generation DMTs by 1995. DMT efficiency was confirmed by a downward turn of the annual trajectory of the risk of SPMS conversion after 1995. An onset age determined pattern of variable SPMS incidence in higher age appeared in both treated and untreated strata. While first generation DMT delayed conversion to SPMS, their long-term effect was only moderate.

Ort, förlag, år, upplaga, sidor
Elsevier, 2022. Vol. 68, artikel-id 104220
Nyckelord [en]
Annual incidence, Disease-modifying therapy, Multiple sclerosis, Observational study, Secondary progression
Nationell ämneskategori
Neurologi
Identifikatorer
URN: urn:nbn:se:umu:diva-200572DOI: 10.1016/j.msard.2022.104220ISI: 000881824300005PubMedID: 36242804Scopus ID: 2-s2.0-85139846258OAI: oai:DiVA.org:umu-200572DiVA, id: diva2:1707285
Forskningsfinansiär
Västra GötalandsregionenTillgänglig från: 2022-10-31 Skapad: 2022-10-31 Senast uppdaterad: 2023-09-05Bibliografiskt granskad

Open Access i DiVA

fulltext(1824 kB)143 nedladdningar
Filinformation
Filnamn FULLTEXT01.pdfFilstorlek 1824 kBChecksumma SHA-512
0d4d4fe2429c66ef4fbb973862ebac6ce1ee8a0e2d2c11c357a49ac19b11723dcf222e31d39b6830a94ac68838e461a25f23c4af61a013bfc2051c8b3d9b0560
Typ fulltextMimetyp application/pdf

Övriga länkar

Förlagets fulltextPubMedScopus

Person

Sundström, Peter

Sök vidare i DiVA

Av författaren/redaktören
Sundström, Peter
Av organisationen
Neurovetenskaper
I samma tidskrift
Multiple Sclerosis and Related Disorders
Neurologi

Sök vidare utanför DiVA

GoogleGoogle Scholar
Totalt: 144 nedladdningar
Antalet nedladdningar är summan av nedladdningar för alla fulltexter. Det kan inkludera t.ex tidigare versioner som nu inte längre är tillgängliga.

doi
pubmed
urn-nbn

Altmetricpoäng

doi
pubmed
urn-nbn
Totalt: 336 träffar
RefereraExporteraLänk till posten
Permanent länk

Direktlänk
Referera
Referensformat
  • apa
  • ieee
  • vancouver
  • Annat format
Fler format
Språk
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Annat språk
Fler språk
Utmatningsformat
  • html
  • text
  • asciidoc
  • rtf